Crossref
Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients
Journal of Enterocolitis · 2026
DOI: 10.14744/jenterocolitis.2026.80717 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enterocolitis, 2026. Verfasst von Narmin Naghizade und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Naghizade, N., Tolu, T., Alahdab, Y. Ö., Atuğ, Ö., & Kani, H. T. (2026). Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients. Journal of Enterocolitis. https://doi.org/10.14744/jenterocolitis.2026.80717
Vancouver
Naghizade N, Tolu T, Alahdab YÖ, Atuğ Ö, Kani HT. Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients. Journal of Enterocolitis. 2026. doi:10.14744/jenterocolitis.2026.80717
BibTeX
@article{Naghizade2026,
author = {Naghizade, Narmin and Tolu, Tuğba and Alahdab, Yeşim Özen and Atuğ, Özlen and Kani, Haluk Tarık},
title = {Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients},
journal = {Journal of Enterocolitis},
year = {2026},
doi = {10.14744/jenterocolitis.2026.80717}
}
EUVIMED